

## **A-tDCS over DLPFC is no more effective than placebo in improving cognition and pain-experience in chronic lower back pain**

Emily J. Corti, Curtin University

Welber Marinovic, Curtin University

An T. Nguyen, Curtin University

Natalie Gasson, Curtin University

Andrea M. Loftus, Curtin University

### **Abstract**

Chronic pain is associated with deficits in cognitive functioning and increased pain intensity. Research investigating the potential for transcranial direct current stimulation (tDCS) to improve cognitive functioning, pain experience, and psychological health in individuals with chronic lower back pain (CLBP) yield mixed results. The present randomised, placebo-controlled study examined the impact of anodal-tDCS over left-dorsolateral prefrontal cortex (left-DLPFC) on cognitive functioning, pain experience, and psychological health in those with CLBP. Thirty participants with CLBP (Mage = 57.47 years, SDage = 14.28 years) received 20-minutes of sham or anodal tDCS, twice weekly, for 4 weeks. Cognitive functioning was assessed using two measures for each of the five cognitive domains; memory, attention and working memory, executive function, visuospatial, and language. Cognition, pain experience, and psychological health were assessed prior to and immediately following the tDCS intervention. Linear Mixed Models revealed a significant tDCS group and time interaction on an attention and working memory task, whereby participants in the a-tDCS showed a significant improvement on the letter number sequencing task at post-intervention. There was a significant main effect of time for both tDCS groups across the five cognitive domains. Both groups demonstrated a significant improvement on at least one measure for each of the five cognitive domains. Linear Mixed Models revealed there was a significant main effect of time for both tDCS groups on pain intensity, disability, catastrophising, anxiety, and stress, whereby both groups demonstrated a significant reduction on these outcome measures. There was a significant main effect of time for both tDCS groups on quality of life, whereby both groups demonstrated a significant improvement in quality of life. There was no significant main effect of tDCS group or interaction between tDCS group and time on pain intensity, disability, catastrophising, anxiety, stress, and quality of life. These findings suggest anodal-tDCS over left-DLPFC is no more effective than sham-tDCS in improving cognition, pain experience, and psychological health in those with CLBP.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## Introduction

Chronic lower back pain (CLBP) is a multidimensional condition characterised by alterations in cognition, psychological health, and quality of life. However, current recommended treatments typically focus only on pain and physical symptoms of the condition. These treatments usually result in small to modest improvements in the short-term but are ineffective for long-term pain management (Chou et al., 2017). It has been suggested that management of CLBP should encompass a biopsychosocial approach that aims to improve not only pain experience, but also functionality (cognition and disability) and psychological wellbeing (mood and quality of life; Cuomo et al., 2021).

The prefrontal cortex plays a key role in pain modulation (Lorenz et al., 2003). Functional imaging studies have revealed that the dorsolateral prefrontal cortex (DLPFC) is involved in both pain modulation (Brighina et al., 2011) and the cognitive evaluation of pain (Melzack, 2001; Mylius et al., 2006). Research suggests that the processing of pain engages significant neural resources in the DLPFC. Consequently, there are fewer neural resources available for other cognitive functions of the DLPFC, such as planning and working memory (Berryman et al., 2013; Seminowicz & Davis, 2007). It has also been suggested that decreased cortical inhibition extends the duration of activation in the DLPFC during pain processing. During this time, the DLPFC is unable to shift attention away from the pain and reallocate those resources to other cognitive tasks (Berryman et al., 2013). Attending to pain is therefore highly cognitively demanding and leaves little resources available in the DLPFC for normal functioning (Moseley, 2003; Smith & Ayres, 2014)

Research has provided strong evidence of cognitive deficits in people with chronic pain (Higgins et al., 2018). However, there are discrepancies regarding which cognitive domains are affected and whether this differs between pain conditions. Compared to controls, people with chronic pain perform poorly on general measures of cognition (Oosterman et al., 2010; Weiner et al., 2006) and the prevalence of significant global deficit ( $\leq 24$  on the Mini Mental State Examination) is higher in the chronic pain population compared to the general population (Povedano et al., 2007; Rodriguez-Andreu et al., 2009). Deficits in attention have been reported in multiple chronic pain conditions, including CLBP (Dick & Rashiq, 2007) and Fibromyalgia (Dick et al., 2002). A systematic and meta-analytic review reported working memory deficits in multiple chronic pain conditions, including CLBP and non-specific CLBP (Berryman et al., 2013). Specific differences between people with chronic pain and healthy controls were reported in verbal working memory, non-verbal working memory, and attention (Berryman et al., 2013). However, no differences were identified in

spatial working memory between people with chronic pain and healthy controls (Berryman et al., 2013). In comparison, a review by Moriarty et al. (2011) reported that people with chronic pain performed poorly on measures of verbal and spatial working memory. These findings were consistent with research in CLBP, that reported deficits in verbal, visual, and spatial memory when compared to pain-free controls (Jorge et al., 2009).

While the specific impairment may differ between pain conditions, cognitive impairment is a common feature of chronic pain that significantly impacts treatment outcomes. Cognitive impairment in people with chronic pain can impact upon a person's planning ability, mental flexibility, and decision making (Apkarian et al., 2004; Berryman et al., 2013; Moriarty et al., 2011), rendering cognitive-behavioural rehabilitation strategies ineffective (Smeets et al., 2006). Poor cognitive performance is associated with disengagement from daily activities, reduced treatment adherence, and poor quality of life in people with chronic pain (Hoy et al., 2014, Roth et al., 2005). As such, effective management of chronic pain needs to encompass strategies to improve cognitive function.

Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that delivers low intensity electrical currents to modulate neural activity (Nitsche et al., 2008). Anodal-tDCS (a-tDCS) over left-DLPFC improves cognitive function in numerous conditions, such as neurodegenerative disease, and healthy ageing (Boggio et al., 2006; Boggio et al., 2009; Coffman et al., 2014). Research in healthy individuals has found that tDCS over DLPFC improves cognitive functioning (Coffman et al., 2014). Participants who experience problems with their memory show improved cognitive functioning across multiple cognitive domains following a-tDCS over DLPFC (Hansen, 2012). Research in neurodegenerative diseases has also reported improvements in cognitive functioning following a-tDCS over DLPFC (Boggio et al., 2006; Boggio et al., 2009; Hansen, 2012). Participants with Parkinson's disease improved on a working memory task following a single session of a-tDCS over DLPFC (Boggio et al., 2006). Participants with Alzheimer's improved on a visual recognition memory task following a single session of a-tDCS over DLPFC (Boggio et al., 2009). While there is substantial evidence for the use of tDCS over left-DLPFC to improve cognition in clinical and healthy ageing populations, few studies have investigated the impact of tDCS on cognitive functioning in chronic pain.

Research in fibromyalgia indicated a trend towards improvement in global cognition following five daily sessions of a-tDCS over DLPFC (Fregni et al., 2006). Improvements were also shown on an attention and working memory task, and simple reaction time task (Fregni et al., 2006). Silva et al. (2017) reported improvements in selective attention

(orientating and executive) in people with fibromyalgia following a single session of a-tDCS over DLPFC. It is believed that a-tDCS induces long-term potentiation-like plasticity mediated by upregulating N-methyl-d-aspartate (NMDA) and GABA receptor activity. These receptors play a key role in maintaining optimal cognitive function (Seminowicz et al., 2019). In chronic pain, a-tDCS over left-DLPFC is thought to inhibit the allocation of maladaptive cognitive and attentional resources to pain, such that people disengage their attention from their pain and assign those resources to other cognitive functions (Berryman et al., 2013; Smith & Ayres, 2014). For those with chronic pain, the inhibition of maladaptive cognitive evaluations of pain may help to alleviate the pain and improve cognitive functioning. However, the impact of tDCS over DLPFC on cognition has not yet been examined in CLBP.

Limited studies have shown tDCS over DLPFC improves cognitive functioning in certain chronic pain conditions (Fregni et al., 2006; Silva et al., 2017). A-tDCS over DLPFC reduces pain levels in some forms of chronic pain (Brietzke et al., 2020; To et al., 2017). It is unclear whether a-tDCS over left-DLPFC can improve cognitive functioning in people with CLBP and, if so, whether there is a corresponding improvement in pain-related outcomes and psychological health. For the present study, it was proposed that 2x weekly, 1.5mA a-tDCS over left- DLPFC for 4 weeks would improve cognitive function in people with CLBP, whereby participants in the a-tDCS group would demonstrate an increase in cognitive performance compared to a sham-tDCS group (s-tDCS). It was also proposed that the a-tDCS group would demonstrate a reduction in pain-related outcomes (pain intensity, disability, and pain catastrophising), compared to the s-tDCS group. Finally, it was proposed that the a-tDCS group would demonstrate an improvement in psychological outcomes (depression, stress, anxiety, and quality of life) compared to the s-tDCS group.

## **Methods**

### **Participants**

Participants were recruited to participate in a 5-week intervention study. This study was approved by Curtin University Human Research Ethics Committee (HR17/2015) and all research was conducted in accordance with the Declaration of Helsinki. All participants provided written, informed consent. Inclusion in the study required a formal diagnosis of CLBP by a qualified health professional (General Practitioner or Physiotherapist) of at least 6 months (see Table 5.1 for demographics and pain related information). Individuals' eligibility was assessed against a tDCS screening questionnaire (Nitsche et al., 2008) and individuals were screened for cognitive status using the Telephone Interview for Cognitive Status – 30 (TICS-30; score  $\geq 18$  for inclusion). Thirty-one participants met the inclusion criteria. One


participant withdrew from the study prior to the first session of the intervention and was not included in the analysis. Thirty participants completed the intervention (see Figure 5.1).

**Table 5.1**

*Baseline demographics and pain-related information by intervention group.*

|                                      | Total (n = 30) | Anodal (n = 15) | Sham (n = 15) |
|--------------------------------------|----------------|-----------------|---------------|
| Age                                  | 57.47 (14.28)  | 52.13 (15.26)   | 62.80 (11.95) |
| Years of Education                   | 12.56 (3.17)   | 11.83 (3.19)    | 13.30 (3.09)  |
| Duration of Diagnosis (years)        | 16.33 (13.69)  | 14.42 (12.67)   | 18.23 (15.28) |
| VAS Pain Average                     | 4.96 (1.95)    | 5.05 (1.73)     | 4.86 (2.21)   |
| CLBP Classification                  |                |                 |               |
| Non-Specific                         | 84%            | 87%             | 80%           |
| Specific                             | 13%            | 13%             | 13%           |
| Neurological                         | 3%             | -               | 7%            |
| Percentage taking Pain Medication    | 64%            | 60%             | 67%           |
| Anti-Inflammatory (Celebrex)*        | 30%            | 78%             | 20%           |
| Pain Killer (Tremadol)*              | 79%            | 67%             | 90%           |
| Benzodiazepine (Valium)*             | 21%            | 44%             | 10%           |
| Anti-Depressants (Endep)*            | 16%            | 22%             | 10%           |
| Engaging in Physiotherapy            | 47%            | 53%             | 40%           |
| Past Surgery                         | 20%            | 27%             | 13%           |
| Other Pain Management (Chiropractor) | 77%            | 87%             | 67%           |
| Depression and Anxiety Disorder      | 20%            | 20%             | 20%           |
| Anti-Anxiety Medication*             | 33%            | 67%             | -             |

*Note.* CLBP Classification = classification of chronic lower back pain based on Koes *et al* (2001), Non-Specific = no radiographical injury at time of participation, Specific = Radiographical evidence, Neurological = related to change in the Central Nervous System. Pain Average = Average pain intensity one week prior to participation. Other = Acupuncture, Chiropractor, Massage. \* = Percentage based on individuals taking pain medication



**Figure 5.1.** Flow diagram of the progress of the trial for anodal and sham transcranial direct current stimulation (tDCS) groups.

### General Procedure

Demographic and pain-related information were collected via self-report questionnaire. All participants were asked to continue their normal medication routine. Neuropsychological and clinical measures were completed at baseline and immediately following the 4-week brain stimulation. Neuropsychological measures took approximately 2.5 hours to complete.

### Measures

Age, sex, level of education, diagnosis duration, and medication use were collected via self-report questionnaire. All participants completed the neuropsychological and clinical assessment. In accordance with DSM-5, and Movement Disorder Society criteria recommendations for mild cognitive impairment, two measures were administered for each of the five cognitive domains (American Psychiatric Association, 2013; Litvan et al., 2012).

## Neuropsychological Assessment

The neuropsychological measures have been previously reported (see Corti et al., 2021).

## Clinical and Pain-related Measures

**Pain experience.** The *Short-Form McGill Pain Questionnaire* (SF-MPQ) contains a 10 cm Visual Analogue Scale (VAS; scored 0 – 10) used to assess average pain intensity over the last week in CLBP (Melzack, 1975). The VAS is a unidimensional measure of pain intensity and participants were required to mark the line at the spot they felt represented their level of pain (Hawker et al., 2011). An individual VAS was used to assess current pain intensity in those with CLBP (Price et al., 1983). Participants completed the individual VAS prior to each intervention session.

**Disability.** The *Roland-Morris Disability Questionnaire* (RMDQ) assessed the level of disability in CLBP (Roland & Morris, 1983). The RMDQ consists of 24 items assessing the impact of CLBP across multiple domains (mobility, daily activities, sleeping, mood, and appetite) with higher scores reflective of greater disability. The RMDQ has high internal consistency in people with CLBP ( $\alpha = .93$ ; Rocchi et al., 2005).

**Depression.** The *Depression, Anxiety, and Stress Scale-21* (DASS-21) assessed the presence of depression, anxiety, and stress in CLBP (Lovibond & Lovibond, 1995). The DASS-21 consists of 21 items assessing depression, anxiety, and stress over the past seven days, with higher scores indicative of greater levels of depression, anxiety, and stress (Lovibond & Lovibond, 1995). The DASS subscales have high internal consistency in people with chronic pain, depression ( $\alpha = .96$ ), anxiety ( $\alpha = .89$ ), and stress ( $\alpha = .95$ ; Taylor et al., 2005).

**Quality of Life.** The MOS 36-Item Short-Form Health Survey (SF-36) assessed QOL in individuals with CLBP (Ware & Sherbourne, 1992). The SF-36 consists of eight subscales (scored from 0 – 100; higher scores indicative of better quality of life); physical functioning, role-physical, bodily pain, mental health, role-emotional, social functioning, vitality, and general health perceptions (McHorney, Ware & Raczek, 1993). The SF-36 has high internal consistency for the eight subscales in people with chronic pain; physical functioning ( $\alpha = .92$ ), role-physical ( $\alpha = .90$ ), bodily pain ( $\alpha = .86$ ), general health ( $\alpha = .81$ ), vitality ( $\alpha = .77$ ), social functioning ( $\alpha = .64$ ), role-emotional ( $\alpha = .87$ ), and mental health ( $\alpha = .80$ ; Picavet & Hoeymans, 2004).



## **Brain Stimulation**

As reported in Corti et al. (2022), participants completed 8-sessions of tDCS stimulation over 4-weeks (2 sessions per week). tDCS was delivered using a constant current stimulator (Soterix®). Participants were randomly assigned (1:1 using block randomisation) to the anodal (a)-tDCS or sham (s)-tDCS group. Participants in the a-tDCS group received 20 minutes of constant 1.5 mA stimulation over left DLPFC every session. The stimulation was administered using two 35 cm<sup>2</sup> sponge electrodes soaked in saline solution. The anode electrode was placed over F3 according to the 10-20 international system for EEG electrode placement, to stimulate the left DLPFC. The reference electrode was placed above the left eye, to ensure the current flowed through the prefrontal area. There was a period of 30 seconds at the beginning and end of the tDCS for ramp up/down. Participants in the s-tDCS experienced the 30 second ramp up/down of tDCS but the stimulation was ceased after the 30 seconds. The ramping up of the tDCS aims to provide participants with the initial experience of receiving active tDCS (Ambrus et al., 2012; Nitsche et al., 2008).

## **Statistical Analysis**

All analyses were conducted using R software (v4.1.2; R Foundation for Statistical Computing, Vienna, Austria).

## **Neuropsychological Analysis**

Cognition data were analysed using linear mixed models using lme function, nlme package, with the nlme default covariance structure (variance components structure; Pinheiro et al., 2022). For all models, tDCS group (2 levels, Active and Sham), time (2 levels, pre and post), and their interactions were included as fixed factors with the intercept of each participant modelled as a random effect.

## **Clinical and Pain-related Measures Analysis**

Pain Intensity, RMDQ score, Pain Catastrophising, Depression, Stress, Anxiety, and Quality of Life subscales were analysed using linear mixed models (Pinheiro et al., 2022). For all models, tDCS group, time, and their interactions were included as fixed factors with the intercept of each participant modelled as a random effect.

## **Results**

### **Memory**

**Hooper Verbal Language Test (HVLT) Total Recall.** The linear mixed model revealed no significant main effect of Group ( $p = .637$ ) or Group and Time Interaction ( $p = .481$ ). There was a significant main effect of Time,  $F(1,28) = 28.12, p < .001$ . Further




inspection of the plots suggests this was driven by an increase in total recall score at post-intervention for both groups (see figure 5.2a).

**HVLT Delayed Recall.** The linear mixed model revealed no significant main effect of Group ( $p = .338$ ), Time ( $p = .067$ ) or Group and Time Interaction ( $p = .381$ ; see figure 5.2a).

**Paragraph Total Recall.** The linear mixed model revealed no significant main effect of Group ( $p = .250$ ), Time ( $p = .120$ ) or Group and Time Interaction ( $p = .429$ ; see figure 5.2b).

**Paragraph Delayed Recall.** The linear mixed model revealed no significant main effect of Group ( $p = .213$ ) or Group and Time Interaction ( $p = .744$ ). There was a significant main effect of Time,  $F(1,28) = 6.48$ ,  $p = .017$ . Further inspection of the plots suggests this was driven by an increase in total recall score at post-intervention for both groups (see figure 5.2b).




**Figure 5.2.** (A) Total and delayed recall score on the Hooper Verbal Language Test pre- and post-intervention by group. (B) Total and delayed recall score on the Paragraph Recall task pre- and post-intervention by group.

### Attention and Working Memory

**Letter Number Sequencing.** The linear mixed model revealed there was no significant main effect of Group ( $p = .220$ ). There was a significant main effect of time,  $F(1, 28) = 18.04$ ,  $p < .001$ . There was a significant interaction between Group and Time,  $F(1, 28) =$

7.67,  $p = .010$ , such that the total score on the LNS task significantly increased in the a-tDCS group at post-intervention see figure 5.3a).

**Stroop.** The linear mixed model revealed no significant main effect of Group ( $p = .970$ ), Time ( $p = .209$ ) or Group and Time Interaction ( $p = .081$ ; see figure 5.3b).




**Figure 5.3.** (A) Total score on the Letter Number Sequencing pre- and post-intervention by group. (B) Total score on the Stroop task pre- and post-intervention by group.

### Executive Function

**Controlled Oral Word Association Task.** The linear mixed model revealed no significant main effect of Group ( $p = .621$ ) or Group and Time Interaction ( $p = .177$ ). There was a significant main effect of Time,  $F(1, 28) = 5.54$ ,  $p = .026$ . Further inspection of the plots suggests this was driven by an increase in total score at post-intervention for both groups (see figure 5.4a).

**Stockings of Cambridge.** The linear mixed model revealed no significant main effect of Group ( $p = .115$ ), Time ( $p = .926$ ) or Group and Time Interaction ( $p = .926$ ; see figure 5.4b).




**Figure 5.4.** (A) Total score on the Controlled Oral Word Association Task (COWAT) pre- and post-intervention by group. (B) Total score on the Stockings of Cambridge pre- and post-intervention by group.

## Visuospatial

**Judgement of Line Orientation.** The linear mixed model revealed no significant main effect of Group ( $p = .805$ ) or Group and Time Interaction ( $p = .791$ ). There was a significant main effect of Time,  $F(1, 28) = 4.36, p = .046$ . Further inspection of the plots suggests this was driven by an increase in total score at post-intervention for both groups (see figure 5.5a).

**Hooper Visual Organisation Test.** The linear mixed model revealed no significant main effect of Group ( $p = .848$ ) or Group and Time Interaction ( $p = .725$ ). There was a significant main effect of Time,  $F(1, 28) = 18.60, p = .< .001$ . Further inspection of the plots suggests this was driven by an increase in total score at post-intervention for both groups (see figure 5.5b).




**Figure 5.5.** (A) Total score on the Judgement of Line Orientation task pre- and post-intervention by group. (B) Total score on the Hooper Visual Organisation Test pre- and post-intervention by group.

### Language

**Boston Naming Test.** The linear mixed model revealed no significant main effect of Group ( $p = .056$ ) or Group and Time Interaction ( $p = .516$ ). There was a significant main effect of Time,  $F(1, 28) = 17.85$ ,  $p < .001$ . Further inspection of the plots suggests this was driven by an increase in total score at post-intervention for both groups (see figure 5.6a).

**Similarities.** The linear mixed model revealed no significant main effect of Group ( $p = .280$ ) or Group and Time Interaction ( $p = .128$ ). There was a significant main effect of Time,  $F(1, 28) = 23.40$ ,  $p < .001$ . Further inspection of the plots suggests this was driven by an increase in total score at post-intervention for both groups (see figure 5.6b).



### Pain-related


**Figure 5.6. (A)** Total score on the Boston Naming Test pre- and post-intervention by group.

**(B)** Total score on the Similarities task pre- and post-intervention by group.

### Outcomes

**Pain Intensity.** The linear mixed model revealed no significant main effect of Group ( $p = .570$ ) or Group and Session Interaction ( $p = .865$ ). There was a significant main effect of Session,  $F(1, 28) = 2.94$ ,  $p = .002$ . Further inspection of the plots suggests this was driven by an overall decrease in pain across the intervention sessions for both groups (see figure 5.7a).


The linear mixed model revealed no significant main effect of Group ( $p = .744$ ) or Group and Time (pre-post) Interaction ( $p = .247$ ). There was a significant main effect of Time,  $F(1, 28) = 2.94$ ,  $p = .006$ . Further inspection of the plots suggests this was driven by an overall decrease in pain at post-intervention for both groups (see figure 5.7b).



**Figure 5.7.** (A) Current Pain intensity recorded at baseline, intervention sessions, and post-intervention by group. (B) Average pain intensity pre- and post-intervention by group.

**Disability (RMDQ).** The linear mixed model revealed no significant main effect of Group ( $p = .851$ ) or Group and Time Interaction ( $p = .234$ ). There was a significant main effect of Time,  $F(1, 28) = 4.40$ ,  $p = .045$ . Further inspection of the plots suggests this effect was driven by a decrease in RMDQ total score at post-intervention for both groups (see figure 5.8a).

**Pain Catastrophising.** The linear mixed model revealed no significant main effect of Group ( $p = .075$ ) or Group and Time Interaction ( $p = .981$ ). There was a significant main effect of Time,  $F(1, 28) = 10.48$ ,  $p = .003$ . Further inspection of the plots suggests pain catastrophising was reduced in both groups at post-intervention (see figure 5.8b).



**Figure 5.8.** (A) Total score on the Roland Morris Disability Questionnaire (higher scores = greater level of disability) pre- and post-intervention by group. (B) Total score on the Pain Catastrophising scale (higher scores = greater level of catastrophising) pre- and post-intervention by group.


### Clinical Outcomes

**Anxiety.** The linear mixed model revealed no significant main effect of Group ( $p = .425$ ) or Group and Time Interaction ( $p = .421$ ). There was a significant main effect of Time,  $F(1, 28) = 5.50, p = .026$ . Further inspection of the plots suggests anxiety was reduced for both groups at post-intervention (see figure 5.9).

**Depression.** The linear mixed model revealed no significant main effect of Group ( $p = .343$ ), Time ( $p = .086$ ) or Group and Time Interaction ( $p = .588$ ; see figure 5.9).

**Stress.** The linear mixed model revealed no significant main effect of Group ( $p = .158$ ) or Group and Time Interaction ( $p = .126$ ). There was a significant main effect of Time,  $F(1, 28) = 28.72, p < .001$ . Further inspection of the plots suggests stress was reduced for both groups at post-intervention (see figure 5.9).





**Figure 5.9.** Total score on each subscale of the Depression Anxiety and Stress Scale – 21 pre- and post-intervention by group.

**Quality of Life. Physical Functioning.** The linear mixed model revealed no significant main effect of Group ( $p = .177$ ) or Group and Time Interaction ( $p = .762$ ). There was a significant main effect of Time,  $F(1, 28) = 5.63, p = .025$ . Further inspection of the plots suggests *Physical Functioning* score increased (improved) for both groups at post-intervention (see figure 5.10).

**Physical Health Limitations.** The linear mixed model revealed no significant main effect of Group ( $p = .444$ ) or Group and Time Interaction ( $p = .881$ ). There was a significant main effect of Time,  $F(1,28) = 21.91, p < .001$ . Further inspection of the plots suggests *Physical Health Limitations* score increased (improved) for both groups at post-intervention (see figure 5.10).

**Emotional Health Limitations.** The linear mixed model revealed no significant main effect of Group ( $p = .308$ ) or Group and Time Interaction ( $p = .223$ ). There was a significant main effect of Time,  $F(1, 28) = 5.54, p = .026$ . Further inspection of the plots suggests *Emotional Health Limitations* score increased (improved) for both groups at post-intervention (see figure 5.10).

**Fatigue.** The linear mixed model revealed no significant main effect of Group ( $p = .365$ ) or Group and Time Interaction ( $p = .373$ ). There was a significant main effect of Time,


$F(1, 28) = 15.57, p < .001$ . Further inspection of the plots suggests *Fatigue* score increased (improved) for both groups at post-intervention (see figure 5.10).

*Emotional Well-being.* The linear mixed model revealed no significant main effect of Group ( $p = .232$ ) or Group and Time Interaction ( $p = .820$ ). There was a significant main effect of Time,  $F(1, 28) = 9.57, p = .004$ . Further inspection of the plots suggests *Emotional Well-being* score increased (improved) for both groups at post-intervention (see figure 5.10).

*Social Functioning.* The linear mixed model revealed no significant main effect of Group ( $p = .188$ ), Time ( $p = .331$ ) or Group and Time Interaction ( $p = .137$ ; see figure 5.10).

*Pain.* The linear mixed model revealed no significant main effect of Group ( $p = .970$ ) or Group and Time Interaction ( $p = .090$ ). There was a significant main effect of Time,  $F(1, 28) = 16.68, p < .001$ . Further inspection of the plots suggests pain related quality of life was increased (improved) for both groups at post-intervention (see figure 5.10).

*General Health.* The linear mixed model revealed no significant main effect of Group ( $p = .541$ ) or Group and Time Interaction ( $p = .438$ ). There was a significant main effect of Time,  $F(1, 28) = 7.40, p = .011$ . Further inspection of the plots suggests general health related quality of life was increased (improved) for both groups at post-intervention (see figure 5.10).



**Figure 5.10.** Total score for each subscale of the Medical Outcomes Study 36-Item Short-Form Health Survey (higher scores = greater health-related quality of life) pre- and post-intervention by group.

## Discussion

The present study examined if twice weekly, 1.5mA a-tDCS over left-DLPFC improved cognitive functioning, self-reported measures of pain and disability, and quality of life in people with CLBP. The findings indicate an increase in performance in the Attention/Working memory task, letter number sequencing, for the a-tDCS group. For both tDCS groups, there was a pre-post intervention improvement in the following cognitive domains; memory (immediate and delayed), executive function, visuospatial, and language. The findings also indicate reduced pain intensity, disability, and pain catastrophising for both a-tDCS and s-tDCS groups. Anxiety and stress were also reduced for both groups. For quality of life, there was an improvement in seven of the eight domains (physical functioning, physical health limitations, emotional health limitations, fatigue, emotional wellbeing, pain, and general health) for both groups. No significant differences were found between the a-tDCS and s-tDCS groups on the aforementioned measures at post-intervention, suggesting that twice weekly, 1.5mA a-tDCS over left-DLPFC is no better than s-tDCS for improving cognition, pain-related experience, or quality of life in those with CLBP.

Attention and working memory performance have been shown to be reduced in individuals with chronic pain (including CLBP) when compared to healthy controls (Berryman et al., 2013; Corti et al., 2021; Moore et al., 2019). A-tDCS over left-DLPFC has been shown to improve working memory performance in several populations, including healthy ageing, neurological, and acute and chronic pain conditions. In line with this, the present findings support the use of a-tDCS over left-DLPFC to improve attention and working memory performance in those with CLBP, without having a direct effect on pain-related processes. As pain intensity was reduced in both the a-tDCS group and s-tDCS, the improvement in attention/working memory in the a-tDCS group cannot be solely attributed to a reduction in pain. These findings are in line with previous research that suggests a-tDCS over left-DLPFC improves attention/working memory performance in people with pain through top-down processes via increased activation of the DLPFC and an improved allocation of attentional resources. Improved attention/working memory may lead to an indirect top-down inhibition of nociceptive activity without affecting pain perception (Deldar et al., 2018; Deldar et al., 2019).

In the present study, both a-tDCS and s-tDCS groups improved on memory (immediate and delayed), visuospatial, executive function, and language tasks following the intervention. These findings indicate that a-tDCS over left left-DLPFC does not improve cognitive function any more than sham tDCS. The improvements for both tDCS groups may

be attributed to the placebo effect. It seems reasonable to suggest that the participants in the sham condition, who received 30-seconds of ramp-up stimulation, believed they were in the experimental (anodal) tDCS group. In this case, participants' expectation of the tDCS to improve cognitive functioning may have affected task performance (Bin Dawood et al., 2020). This is in line with previous research suggesting that tDCS has a strong placebo effect, such that it can influence participant behaviour and performance (Bin Dawood et al., 2020; Rabipour et al., 2018). Future studies should consider the use of a no-stimulation group to further explore the placebo effect of tDCS on cognition in CLBP, as s-tDCS alone cannot provide an accurate estimation of the overall influence of a potential placebo effect (Aslaksen et al., 2014; Benedetti et al., 2003). By including a no-stimulation group, the size of the placebo effect in the s-tDCS group can be determined by comparing the effect with the no-intervention group. Additionally, the inclusion of the three groups (a-tDCS, s-tDCS, and no-stimulation group) will inform on the specific effect of tDCS on pain as well as the placebo effect. Another potential explanation for the improvements observed for both groups is a practice effect. Although 5 weeks (the length of the intervention) has been used in previous research (Falleti et al., 2006), it is possible that participants may have recalled some of the tasks at post-intervention. Future studies should consider a longer timeframe between pre and post assessments to reduce the possibility of practice effects and should consider the use of alternate assessment forms (e.g., different, but comparable, word lists at pre and post intervention) to eliminate potential practice effects. Another alternate explanation for the observed improvements may be regression to the mean. Pain can be unpredictable and can fluctuate due to multiple reasons (e.g., acute injury, psychological factors). Additionally, the measurement of pain is subjective and is therefore prone to random variation. As such, regression to the mean cannot be ruled out in the present study.

Pain-related outcomes (intensity, disability, and catastrophising) and psychological outcomes (anxiety, stress, and health-related quality of life) also improved for both groups. This suggests that a-tDCS does not reduce the pain experience or improve psychological outcomes in CLBP any more than can be attributed to the placebo effect. The present findings are in line with research indicating that tDCS-induced placebo reduced and stabilised pain intensity in neuropathic pain for 3 months following stimulation (Tuttle et al., 2015). It has been suggested that the widely observed placebo effect following tDCS is due to positive participant expectations of the treatment. Benedetti et al. (2014) suggested that when analgesia associated with the placebo effect aligns with a participant's expectations of the treatment, an analgesic feedback loop is created, which subsequently maintains the reduction

in pain. Given the reduction in pain across both groups, it is not surprising that self-reported disability and quality of life were also improved across both groups. These findings are consistent with previous tDCS and fibromyalgia research that reported improvements in quality of life in both a-tDCS and s-tDCS groups following tDCS over DLPFC (Fregni et al., 2006; Samartin-Veiga et al., 2022), and that improvements in quality of life were maintained at 6-month follow up (Samartin-Veiga et al., 2022).

The present findings support the growing body of research that suggests the placebo effect can improve chronic pain outcomes, including in CLBP (Chaparro et al., 2014; Henschke et al., 2010; Kleine-Borgmann et al., 2019). Research has reported that placebo treatment has led to improvements in pain-related disability and reduction in pain intensity in people with CLBP (Carvalho et al., 2016; Kleine-Borgmann et al., 2019). This is consistent with the present findings, whereby both a-tDCS and s-tDCS groups reported reduced pain and pain-related disability. The present study also suggests that the placebo effect may be associated with improvements in cognitive functioning and quality of life in people with CLBP. Although the present findings are unable to determine whether these improvements are directly caused by the placebo effect, or a natural consequence of improved pain outcomes, it does suggest that the placebo effect may be therapeutically beneficial not only for pain-related outcomes, but also to improve cognition and psychological wellbeing in people with CLBP. While the use of blinded placebo treatments can raise ethical concerns, this can be avoided by using open-label placebos (Kaptchuk & Miller, 2018). Research investigating the potential therapeutic benefit of the placebo effect in CLBP, found that participants reported clinically significant improvement in pain outcomes, even when participants were aware they were receiving a placebo treatment (open-label placebo; Carvalho et al., 2016; Kleine-Borgmann et al., 2019). Future open-label placebo, randomised controlled trials should examine whether tDCS-induced placebo effect may be of therapeutic benefit for people with CLBP.

### **Limitations**

The present findings should be considered in line with a number of limitations. In accordance with DSM-5 and MDS criteria for identifying mild cognitive impairment, the present study included 10 cognitive tests. The inclusion of so many tests may have inflated the Type I error rate, such that the significant effect of a-tDCS on the attention and working memory task is a natural consequence of the number of tasks used (Loftus et al., 2015). Given the effect of time was also significant, indicating that both the a-tDCS and s-tDCS group improved on the task, it is reasonable to suggest that the improvement in the a-tDCS

group on the attention and working memory tasks may be a combination of the placebo effect and Type I error. Hence, this finding may be a natural consequence of the design of the study. Future research should consider reducing the overall number of tasks, or consider the use of a composite score for each cognitive domain, to reduce the potential for Type I errors (Feise, 2002).

The use of analgesic medications can influence cognitive functioning, pain, and psychological outcomes. While medication use was recorded in the present study, frequency of use and dosage was not documented. It is unknown if medication use was similar, reduced, or increased between pre- and post-intervention. We cannot rule out if changes in analgesic medication use may play some role in the observed improvements in pain-related and psychological outcomes. Previous research has produced conflicting results as to whether the use of analgesic medication hinders or improves cognitive future (Higgins et al., 2018). Future research should consider the inclusion of non-medicated participants to reduce any potential influence of medication on cognitive function. However, this may be difficult to achieve given that chronic pain is usually managed through medication.

The design of the study makes it difficult to differentiate between the effect of tDCS and the effect of engaging in the intervention. Previous research has reported trial characteristics (e.g., the number of visits) were significantly associated with increased placebo response (Tuttle et al., 2015; Vase et al., 2015). Participants in the present study attended 9 appointments over a 5-week period, and it is possible that this may have impacted on both physical and emotional health. Attending the appointments may have increased participants movement and physical functioning and may have increased perceived social support (from the researchers). Research has reported that perceived social support is associated with pain intensity and depression in chronic pain, such that higher levels of perceived social support is associated with reduced pain and depression (López-Martínez et al., 2008). Although the present study did not collect information on perceived social support, it is reasonable to suggest that attending appointments twice weekly to discuss the participants' pain experience, may have increased their level of perceived social support. Future studies should consider modifying the study design to reduce the potential confounding impact of study-related effects of the intervention (e.g., reduce face-to-face appointments, or utilise home appointments). Future research should also consider including a no-intervention group, who receive the same level of social support as the intervention group, to examine if improvements in pain-related outcomes may be associated with an increase in perceived social support.



## **Conclusion**

The present findings suggest that a-tDCS does not improve cognitive function in people with CLBP any more than s-TDCS. Both tDCS groups improved on measures of cognitive functioning, pain-related outcomes, and psychological outcomes, and this is most likely reflective of a strong placebo effect for tDCS. The present findings raise an interesting question as to the potential therapeutic benefit of the placebo effect in CLBP. Not only do current treatment options (pharmacological and surgical interventions) carry significant side-effects, but they are also typically ineffective for long-term pain management. As tDCS is safe and relatively inexpensive, the tDCS-induced placebo effect may be a beneficial approach in the management of CLBP. Further investigation of the potential clinical benefit of tDCS, even if such benefit is the result of placebo, in CLBP is required.

## References

- Ambrus, G. G., Al-Moyed, H., Chaieb, L., Sarp, L., Antal, A., & Paulus, W. (2012). The fade-in--short stimulation--fade out approach to sham tDCS--reliable at 1 mA for naïve and experienced subjects, but not investigators. *Brain Simulation*, 5(4), 499–504. <https://doi.org/10.1016/j.brs.2011.12.001>
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). American Psychiatric Publishing.
- Apkarian, A.V., Sosa, Y., Krauss, B.R., Thomas, P.S., Fredrickson, B.E., Levy, R.E., Harden, R.N., & Chialvo, D.R. (2004). Chronic pain patients are impaired on an emotional decision-making task. *Pain*, 108, 129-136. doi:10.1016/j.pain.2003.12.015
- Aslaksen, P. M., Vasylenko, O., & Fagerlund, A. J. (2014). The effect of transcranial direct current stimulation on experimentally induced heat pain. *Experimental Brain Research*, 232(6), 1865–1873. <https://doi.org/10.1007/s00221-014-3878-0>
- Benedetti F. (2014). Placebo effects: From the neurobiological paradigm to translational implications. *Neuron*, 84(3), 623–637. <https://doi.org/10.1016/j.neuron.2014.10.023>
- Benedetti, F., Pollo, A., Lopiano, L., Lanotte, M., Vighetti, S., & Rainero, I. (2003). Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. *Journal of Neuroscience*, 23, 4315-4323. <https://doi.org/10.1523/JNEUROSCI.23-10-04315.2003>
- Berryman, C., Staton, T. R., Bowering, K. J., Tabor, A., McFarlane, A., & Moseley, G. L. (2013). Evidence for working memory deficits in chronic pain: A systematic review and meta-analysis. *Pain*, 154, 1181-1196. <https://doi.org/10.1016/j.pain.2013.0.002>
- Bin Dawood, A., Dickinson, A., Aytumur, A., Howarth, C., Milne, E., & Jones, M. (2020). Investigating the effects of tDCS on visual orientation discrimination task performance: “the possible influence of placebo”. *Journal of Cognitive Enhancement*, 4, 235–249. <https://doi.org/10.1007/s41465-019-00154-3>
- Boggio, P. S., Ferrucci, R., Rigonatti, S. P., Covre, P., Nitsche, M., Pascual-Leone, A., & Fregni, F. (2006). Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. *Journal of the Neurological Sciences*, 249, 31-38. <https://doi.org/10.1016/j.jns.2006.05.062>
- Boggio, P. S., Khoury, L. P., Martins, D. C., Martins, O. E., De Macedo, E., & Fregni, F. (2009). Temporal cortex direct current stimulation enhances performance on a visual recognition memory task in Alzheimer disease. *Journal of Neurology, Neurosurgery & Psychiatry*, 80, 444-447. doi:10.1136/jnnp.2007.141853

- Brietzke, A. P., Zortea, M., Carvalho, F., Sanches, P., Silva, D., Torres, I., Fregni, F., & Caumo, W. (2020). Large treatment effect with extended home-based transcranial direct current stimulation over dorsolateral prefrontal cortex in fibromyalgia: A proof of concept sham-randomized clinical study. *The Journal of Pain*, *21*(1-2), 212–224. <https://doi.org/10.1016/j.jpain.2019.06.013>
- Brighina, F., De Tommaso, M., Giglia, F., Scalia, S., Cosentino, G., Puma, A., Panetta, M., Giglia, G., & Fierro, B. (2011). Modulation of pain perception by transcranial magnetic stimulation of left prefrontal cortex. *Journal of Headache Pain*, *12*, 185–191. <https://doi.org/10.1007/s10194-011-0322-8>
- Carvalho, C., Caetano, J. M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2016). Open-label placebo treatment in chronic low back pain: A randomized controlled trial. *Pain*, *157*(12), 2766–2772. <https://doi.org/10.1097/j.pain.0000000000000700>
- Chaparro, L. E., Furlan, A. D., Deshpande, A., Mailis-Gagnon, A., Atlas, S., & Turk, D. C. (2014). Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. *Spine*, *39*(7), 556–563. <https://doi.org/10.1097/BRS.0000000000000249>
- Chou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017). Systemic pharmacologic therapies for low back pain: A systematic review for an American College of Physicians clinical practice guideline. *Annals of Internal Medicine*, *166*(7), 480–492. <https://doi.org/10.7326/M16-2458>
- Coffman, B. A., Clark, V. P., & Parasuraman, R. (2014). Battery powered thought: Enhancement of attention, learning, and memory in healthy adults using transcranial direct current stimulation. *Neuroimage*, *85*, 895–908. <https://doi.org/10.1016/j.neuroimage.2013.07.083>
- Corti, E. J., Gasson, N., & Loftus, A. M. (2021). Cognitive profile and mild cognitive impairment in people with chronic lower back pain. *Brain and Cognition*, *151*, 105737. <https://doi.org/10.1016/j.bandc.2021.105737>
- Corti, E. J., Nguyen, A. T., Marinovic, W., Gasson, N., & Loftus, A. M. (2022). Anodal-tDCS over left-DLPFC modulates motor cortex excitability in people with chronic lower back pain. *Brain Sciences*, *12*, 1654. <https://doi.org/10.3390/brainsci12121654>
- Cuomo, A., Cascella, M., Vittori, A., & Marinangeli (2021). Chronic low back pain as a biopsychosocial disease: time to change our point of view. *Journal of Anesthesia Analgesia and Critical Care*, *1*, 7. <https://doi.org/10.1186/s44158-021-00010-x>

- De Amici, D., Klersy, C., Ramajoli, F., Brustia, L., & Politi, P. (2000). Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. *Controlled Clinical Trials*, 21(2), 103–114. [https://doi.org/10.1016/s0197-2456\(99\)00054-9](https://doi.org/10.1016/s0197-2456(99)00054-9)
- Deldar, Z., Rustamov, N., Blanchette, I., & Piché, M. (2019). Improving working memory and pain inhibition in older persons using transcranial direct current stimulation. *Neuroscience research*, 148, 19–27. <https://doi.org/10.1016/j.neures.2018.12.007>
- Deldar, Z., Rustamov, N., Bois, S., Blanchette, I., & Piché, M. (2018). Enhancement of pain inhibition by working memory with anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex. *The Journal of Physiological Sciences*, 68(6), 825–836. <https://doi.org/10.1007/s12576-018-0598-4>
- Dick, B., Eccleston, C., & Crombez, G. (2002). Attentional functioning in fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. *Arthritis Care & Research*, 47(6), 639-644. <https://doi.org/10.1002/art.10800>
- Dick, B. D., & Rashiq, S. (2007). Disruption of attention and working memory traces in individuals with chronic pain. *Anesthesia and Analgesia*, 104(5), 1223-1229. <https://doi.org/10.1213/01.ane.0000263280.49786.f5>
- Feise, R.J. (2002). Do multiple outcome measures require p-value adjustment? *BMC Medical Research Methodology*, 2, 8-11 (2002). <https://doi.org/10.1186/1471-2288-2-8>
- Fregni, F., Gimenes, R., Valle, A.C., Ferreira, M.J., Rocha, R.R., Natalle, L., Bravo, R., Rigonatti, S.P., Freedman, S.D., Nitsche, M.A., Pascual-Leone, A., & Boggio, P.S. (2006). A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. *Arthritis & Rheumatism*, 54, 3988-3998. <https://doi.org/10.1002/art.2219538>
- Hansen, N. (2012). Action mechanisms of transcranial direct current stimulation in Alzheimer's disease and memory loss. *Frontiers in Psychiatry*, 3, 1-8. <https://doi.org/10.3389/fpsy.2012.00048>
- Hawker, G.A., Mian, S., Kendzerska, T., & French, M. (2011). Measures of adult pain: visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), mcgill pain questionnaire (MPQ), short-form mcgill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). *Arthritis Care and Research*, 63, 240-252. <https://doi.org/10.1002/acr.2054339>
- Henschke, N., Ostelo, R. W., van Tulder, M. W., Vlaeyen, J. W., Morley, S., Assendelft, W. J., & Main, C. J. (2010). Behavioural treatment for chronic low-back pain. *The*

*Cochrane Database of Systematic Reviews*, 2010(7), CD002014.

<https://doi.org/10.1002/14651858.CD002014.pub3>

- Higgins, D. M., Martin, A. M., Baker, D. G., Vasterling, J. J., & Risbrough, V. (2018). The relationship between chronic pain and neurocognitive function: A systematic review. *The Clinical Journal of Pain*, 34(3), 262–275.  
<https://doi.org/10.1097/AJP.0000000000000536>
- Hoy, D., March, L., Brooks, P., Blyth, F., Woolf, A., Bain, C., Williams, G., Smith, E., Vos, T., Barendregt, J., Murray, C., Burstein, R., & Buchbinder, R. (2014). The global burden of low back pain: estimates from the global burden of disease 2010 study. *Annals of the Rheumatic Diseases*, 73, 968-974. <https://doi.org/10.1136/annrheumdis-2013-204428>
- Jorge, L. L., Gerard, C., & Revel, M. (2009). Evidences of memory dysfunction and maladaptive coping in chronic low back pain and rheumatoid arthritis patients: Challenges for rehabilitation. *European Journal of Physical and Rehabilitation Medicine*, 45, 469-477. <https://pubmed.ncbi.nlm.nih.gov/20032904/>
- Kaptchuk, T. J., & Miller, F. G. (2018). Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits? *BMJ (Clinical Research Ed.)*, 363, k3889.  
<https://doi.org/10.1136/bmj.k3889>
- Kleine-Borgmann, J., Schmidt, K., Hellmann, A., & Bingel, U. (2019). Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: A randomized controlled trial. *Pain*, 160(12), 2891–2897.  
<https://doi.org/10.1097/j.pain.0000000000001683>
- Koes, B.W., Van Tulder, M.W., Ostelo, R., Burton, A.K., & Waddell, G. (2001). Clinical guidelines for the management of low back pain in primary care: an international comparison. *Spine*, 26, 2504–2513. <https://doi.org/10.1097/00007632-200111150-00022>
- Litvan, I., Goldman, J.G., Tröster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., Mollenhauer, B., Adler, C.H., Marder, K., Williams-Gray, C.H., Aarsland, D., Kulisevsky, J., Rodriguez-Oroz, M.C., Burn, D.J., Barker, R.A., & Emre, M. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Movement Disorders*, 27, 349–356.  
<https://doi.org/10.1002/mds.24893>
- Loftus, A.M., Bucks, R.S., Thomas, M., Kane, R., Timms, C., Barker, R.A., & Gasson, N. (2015). Retrospective assessment of movement disorder society criteria for mild

- cognitive impairment in Parkinson's disease. *Journal of the International Neuropsychological Society*, 21(2), 137-145.  
<https://doi.org/10.1017/S1355617715000041>
- López-Martínez, A. E., Esteve-Zarazaga, R., & Ramírez-Maestre, C. (2008). Perceived social support and coping responses are independent variables explaining pain adjustment among chronic pain patients. *Journal of Pain*, 9(4), 373–379.  
<https://doi.org/10.1016/j.jpain.2007.12.002>
- Lorenz, J., Minoshima, S., & Casey, K. (2003). Keeping pain out of mind: the role of the dorsolateral prefrontal cortex in pain modulation. *Brain*, 126, 1079-1091.  
<https://doi.org/10.1093/brain/awg10241>
- Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behaviour Research and Therapy*, 33, 335-343.  
[https://doi.org/10.1016/0005-7967\(94\)00075-U](https://doi.org/10.1016/0005-7967(94)00075-U)
- McCambridge, J., Witton, J., & Elbourne, D. R. (2014). Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. *Journal of Clinical Epidemiology*, 67(3), 267–277. <https://doi.org/10.1016/j.jclinepi.2013.08.015>
- McHorney, C. A., Ware, J. E. Jr., & Raczek, A. E. (1994). The MOS 36-Item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Medical Care*, 31, 247-263.
- Melzack, R. (1975). The McGill pain questionnaire: Major properties and scoring methods. *Pain*, 1, 277-299. [https://doi.org/10.1016/0304-3959\(75\)90044-5](https://doi.org/10.1016/0304-3959(75)90044-5)
- Melzack, R. (2001). Pain and the neuromatrix in the brain. *Journal of Dental Education*, 65, 1387-1382.
- Moore, D. J., Meints, S. M., Lazaridou, A., Johnson, D., Franceschelli, O., Cornelius, M., Schreiber, K., & Edwards, R. R. (2019). The effect of induced and chronic pain on attention. *The Journal of Pain*, 20(11), 1353–1361.  
<https://doi.org/10.1016/j.jpain.2019.05.004>
- Moriarty, O., McGuire, B. E., & Finn, D. P. (2011). The effect of pain on cognitive function: a review of clinical and preclinical research. *Progress in Neurobiology*, 93, 385-404.  
<https://doi.org/10.1016/j.pneurobio.2011.01.002>
- Moseley, G. L. (2003). A pain neuromatrix approach to patients with chronic pain. *Manual Therapy*, 8, 130-140. doi:10.1016/S1356X(03)00051-1

- Mylius, V., Reis, J., Kunz, M., Beyer, T., Oertel, W., Rosenow, F., & Schepelmann, K. (2006). Modulation of electrically induced pain by paired pulse transcranial magnetic stimulation of the medial frontal cortex. *Clinical Neurophysiology*, *117*, 1814-1820. <https://doi.org/10.1016/j.clinph.2006.04.013>
- Nitsche, M. A., Cohen, L. G., Wassermann, E. M., Priori, A., Lang, N., Antal, A., Paulus, W., Hummel, F., Boggio, P. S., Fregni, F., & Pascual-Leone, A. (2008). Transcranial direct current stimulation: State of the art 2008. *Brain Stimulation*, *1*, 206-223. <https://doi.org/10.1016/j.brs.2008.06.004>
- Oosterman, J. M., Derksen, L. C., van Wijck, A. J., Veldhuijzen, D. S., & Kessels, R. P. (2011). Memory functions in chronic pain: examining contributions of attention and age to test performance. *The Clinical Journal of Pain*, *27*(1), 70–75. <https://doi.org/10.1097/AJP.0b013e3181f15cf5>
- Picavet, H. S. J., & Hoeymans, N. (2004). Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. *Annals of the Rheumatic Diseases*, *63*, 723-729. <https://doi.org/10.1136/ard.2003.010769>
- Pinheiro J, Bates D, DebRoy S, Sarkar D, & R Core Team (2022). *nlme: Linear and Nonlinear Mixed Effects Models*. R package version 3.1-155, <https://CRAN.R-project.org/package=nlme>
- Povedano, M., Gascón, J., Gálvez, R., Ruiz, M., & Rejas, J. (2007). Cognitive function impairment in patients with neuropathic pain under standard care conditions. *Journal of Pain and Symptom Management*, *33*, 78-89. <https://doi.org/10.1016/j.jpainsymman.2006.07.012>
- Price, D., McGrath, P., Rafii, A., & Buckingham, B. (1983). The validation of visual analogue scales as ratio measures for chronic and experimental pain. *Pain*, *17*, 45-59. [https://doi.org/10.1016/0304-3959\(83\)90126-445](https://doi.org/10.1016/0304-3959(83)90126-445)
- Rabipour, S., Vidjen, P. S., Remaud, A., Davidson, P., & Tremblay, F. (2019). Examining the interactions between expectations and tDCS effects on motor and cognitive performance. *Frontiers in Neuroscience*, *12*, 999. <https://doi.org/10.3389/fnins.2018.00999>
- Rocchi, M. B. I., Sisti, D., Benedetti, P., Valentini, M., Bellagamba, S., & Federici, A. (2005). Critical comparison of nine different self-administered questionnaires for the evaluation of disability caused by low back pain. *European Journal of Physical and Rehabilitation Medicine*, *41*, 275-281.



- Rodríguez-Andreu, J., Ibáñez-Bosch, R., Portero-Vázquez, A., Masramon, X., Rejas, J., & Gálvez, R. (2009). Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. *BMC musculoskeletal disorders*, *10*, 162. <https://doi.org/10.1186/1471-2474-10-162>
- Roland, M. O., & Morris, R. W. (1983). A study of the natural history of back pain. Part 1: Development of a reliable and sensitive measure of disability in low back pain. *Spine*, *8*, 141-144.
- Roth, R., Geisser, M., Theisen-Goodvich, M., & Dixon, P. (2005). Cognitive complaints are associated with depression, fatigue, female sex, and pain catastrophizing in patients with chronic pain. *Archives of Physical Medicine and Rehabilitation*, *86*, 1147-1154. <https://doi.org/10.1016/j.ampr.2004.10.04146>
- Samartin-Veiga, N., Pidal-Miranda, M., González-Villar, A. J., Bradley, C., Garcia-Larrea, L., O'Brien, A. T., & Carrillo-de-la-Peña, M. T. (2022). Transcranial direct current stimulation of 3 cortical targets is no more effective than placebo as treatment for fibromyalgia: a double-blind sham-controlled clinical trial. *Pain*, *163*(7), e850–e861. <https://doi.org/10.1097/j.pain.0000000000002493>
- Seminowicz, D., & Davis, K. (2007). A re-examination of pain-cognition interactions: Implications for neuroimaging. *Pain*, *130*, 8-13. <https://doi.org/10.1016/j.pain.2007.03.036>
- Seminowicz, D. A., & Moayed, M. (2017). The dorsolateral prefrontal cortex in acute and chronic pain. *The Journal of Pain*, *18*(9), 1027–1035. <https://doi.org/10.1016/j.jpain.2017.03.008>
- Silva, A., Zortea, M., Carvalho, S., Leite, J., da Silva Torres, I.L., Fregni, F., Caumo, W. (2017). Anodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex modulates attention and pain in fibromyalgia: randomized clinical trial. *Scientific Reports* *7*, 135. <https://doi.org/10.1038/s41598-017-00185-w>
- Smeets, R. J. E. M., Vlaeyen, J. W. S., Kester, A. D. M., & Knotterus, J. A. (2006). Reduction of pain catastrophizing mediates the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. *Journal of Pain*, *7*, 261-271. <https://doi.org/10.1016/j.jpain.2005.10.011>
- Smith, A., & Ayres, P. (2014). The impact of persistent pain on working memory and learning. *Educational Psychology Review*, *26*, 245-264. <https://doi.org/10.1007/s10648-013-9247-x>

- Taylor, R., Lovibond, P.F., Nicholas, M. K., Cayley, C., & Wilson, P. (2005). The utility of somatic items in the assessment of depression in patients with chronic pain: A comparison of the Zung self-rating depression scale and the depression anxiety stress scale in chronic pain and clinical and community samples. *Clinical Journal of Pain, 21*, 91-100.
- To, W.T., James, E., Ost, J., Hart, J., Jr, De Ridder, D., & Vanneste, S. (2017). Differential effects of bifrontal and occipital nerve stimulation on pain and fatigue using transcranial direct current stimulation in fibromyalgia patients. *Journal of neural transmission, 124*(7), 799–808. <https://doi.org/10.1007/s00702-017-1714-y>
- Tuttle, A. H., Tohyama, S., Ramsay, T., Kimmelman, J., Schweinhardt, P., Bennett, G. J., & Mogil, J. S. (2015). Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. *Pain, 156*(12), 2616–2626.  
<https://doi.org/10.1097/j.pain.0000000000000333>
- Vase, L., Vollert, J., Finnerup, N. B., Miao, X., Atkinson, G., Marshall, S., Nemeth, R., Lange, B., Liss, C., Price, D. D., Maier, C., Jensen, T. S., & Segerdahl, M. (2015). Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. *Pain, 156*(9), 1795–1802. <https://doi.org/10.1097/j.pain.0000000000000217>
- Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. *Medical Care, 30*, 473-483
- Weiner, D. K., Rudy, T. E., Morrow, L., Slaboda, J., & Lieber, S. (2006). The relationship between pain, neuropsychological performance, and physical function in community-dwelling older adults with chronic low back pain. *Pain Medicine, 7*(1), 60–70.  
<https://doi.org/10.1111/j.1526-4637.2006.00091.x>
- Wolfe, F., & Michaud, K. (2010). The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. *The Journal of Rheumatology, 37*(11), 2216–2220. <https://doi.org/10.3899/jrheum.100497>